Assessing the Value of New Treatment Strategies in Inflammatory Bowel Disease: A Review of Clinical Data and Managed Care Implications

Assessing the Value of New Treatment Strategies in Inflammatory Bowel Disease: A Review of Clinical Data and Managed Care Implications

Faculty Presenters

Khalid M. Kamal, MPharm, PhD
Professor and Chair
Department of Pharmaceutical Systems and Policy
West Virginia University School of Pharmacy
Morgantown, West Virginia

Christopher Owens, PharmD, MPH
Associate Professor and Associate Vice President
Kasiska Division of Health Sciences
Idaho State University
Pocatello, Idaho
 
Program Description
Inflammatory bowel disease (IBD) presents with gastrointestinal inflammation and symptoms including diarrhea, abdominal pain, rectal bleeding, and weight loss. These symptoms, as well as other complications of disease, can have a significant impact on a patient’s quality of life and contribute to substantial economic burden. Updated guidance for the treatment of IBD focuses on the use of newer agents to maintain remission of IBD, thereby reducing hospitalizations and use of adjuvant agents to manage IBD exacerbations. As members of the multidisciplinary team, managed care pharmacists must be involved in a coordinated approach to the treatment and management of patients with IBD. They can use their knowledge of emerging data for targeted immune modulators and biologics to develop appropriate patient management strategies according to the most recent guidelines and facilitate their inclusion in clinical practice.

Target Audience: Managed care pharmacists
Type of Activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Determine the incidence and pathophysiology of inflammatory bowel disease (IBD) as well as the burden and challenges associated with IBD management.
• Compare the safety and efficacy data of current and emerging treatments for IBD, including their mechanism of action, dosing, and adverse effects.
• Identify various treatment strategies that managed care professionals can implement to help improve patient adherence, clinical outcomes, and decrease healthcare costs associated with IBD.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-21-164-H01-P. The activity is available for CE credit through April 26, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Faculty

Khalid M. Kamal, MPharm, PhD, and Christopher Owens, PharmD, MPH, have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms